Breaking News, Financial News

Financial Report: Alexion 3Q

Revenues up 44% in the quarter

Alexion

3Q Revenues: $294.1 million (+44%)

3Q Earnings: $92.2 million (+41%)

YTD Revenues: $813.6 million (+46%)

YTD Earnings: $173.9 million (+37%)

Comments: Soliris sales were $294.1 million in the quarter, up 44%. R&D expenses were $54.3 million, compared to $36.6 million in 3Q11. Results were positively impacted by the terms of a patent settlement and license agreement, for which the company recognized a gain of $53.4 million in cost of sales, net of the effect of an upfront payment.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters